<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00128297</url>
  </required_header>
  <id_info>
    <org_study_id>GEICAM 2000-01</org_study_id>
    <nct_id>NCT00128297</nct_id>
  </id_info>
  <brief_title>Pamidronate Administration in Breast Cancer Patients With Bone Metastases</brief_title>
  <official_title>Randomized, Multicentric Phase IV Clinical Trial for the Administration of Pamidronate in Breast Cancer Patients With Bone Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Breast Cancer Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to evaluate the differences, in terms of first occurrence of a
      skeletal event, in patients with breast cancer and symptomatic bone metastases, when
      pamidronate is administered during 2 years, or when it is administered during 6 months,
      followed by a six month rest period, and again a 6 month treatment period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <completion_date>December 2002</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pamidronate efficacy to prevent first skeletal event</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of skeletal events per treatment arm</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life per treatment arm</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <enrollment>120</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Neoplasm Metastasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pamidronate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent.

          -  Up to two previous or current hormone therapy treatments for metastatic breast cancer
             are allowed.

          -  Normal or borderline renal function (serum creatinine &lt; 1.5 x upper normal limit
             [UNL]).

          -  Normal calcium levels in serum, or slightly non-symptomatic high levels (&lt; 1.25 x
             UNL).

          -  Performance status 0, I or II in WHO scale.

        Exclusion Criteria:

          -  Treatment with bisphosphonates in the 30 previous days, or any time if the indication
             was treatment of metastatic bone lesions.

          -  Treatment with bisphosphonates is only allowed if the indication is hypercalcaemia.

          -  Metastases in central nervous system (CNS).

          -  Hypersensitivity to bisphosphonates or other components of the formula.

          -  Pregnant or lactating women.

          -  Previous or current treatment with a second chemotherapy line or a third hormone
             therapy line for metastatic disease.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agustí Barnadas, MD., PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Lluch, MD., PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Clínico Universitario de Valencia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spanish Breast Cancer Research Group (GEICAM)</name>
      <address>
        <city>San Sebastián de los Reyes</city>
        <state>Madrid</state>
        <zip>28700</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.geicam.org</url>
    <description>&quot;Click here for more information about this study:&quot;</description>
  </link>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2005</study_first_submitted>
  <study_first_submitted_qc>August 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2005</study_first_posted>
  <last_update_submitted>September 25, 2009</last_update_submitted>
  <last_update_submitted_qc>September 25, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2009</last_update_posted>
  <keyword>Breast cancer patients with symptomatic bone metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

